Starling Oncology, Inc. Sale of Stock, Consideration Received on Transaction
Starling Oncology, Inc. (DFPH) had Sale of Stock, Consideration Received on Transaction of $275.00 million as of 2021-06-28, per its 10-K filed 2023-03-16.
Discontinued › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2023-03-16
- 2021-06-28: Sale of Stock, Consideration Received on Transaction $275.00M.
| Period end | Sale of Stock, Consideration Received on Transaction |
|---|---|
| 2021-06-28 | $275.00M 10-K · filed 2023-03-16 |